<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895713</url>
  </required_header>
  <id_info>
    <org_study_id>IG302</org_study_id>
    <nct_id>NCT00895713</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation</brief_title>
  <official_title>Efficacy and Safety of Intramuscular Hepatitis B Virus Immune Globulin Grifols for the Prevention of Hepatitis B Virus Recurrence After Orthotopic Liver Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with intramuscular hepatitis B virus
      immune globulin Grifols, a new specific hepatitis B immune globulin, is effective and safe
      for the prevention of hepatitis B virus recurrence after orthotopic liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean trough serum HBsAg Ab titer</measure>
    <time_frame>Months 4-6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV recurrence percentage in long-term OLT recipients during i.m. HBIG Grifols treatment period</measure>
    <time_frame>Week 2 - 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean trough HBsAg Ab titer</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individualised trough HBsAg Ab titer</measure>
    <time_frame>Week 2 - 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with serum HBV DNA-positive samples by DNA PCR-amplification assay</measure>
    <time_frame>Week 2 - 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>im HBIG Grifols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intramuscular hepatitis B virus immune globulin</intervention_name>
    <description>Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months</description>
    <arm_group_label>im HBIG Grifols</arm_group_label>
    <other_name>Igantibe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female.

          2. Age &gt; 18 years and &lt; 70 years.

          3. OLT recipient for HBV infection-related disease for &gt; 18 months before inclusion in
             the clinical trial.

          4. Serum HBsAg-positive within 3 months before transplantation.

          5. Serum HBsAg-negative just before inclusion in the clinical trial.

          6. Serum HbeAg-negative just before inclusion in the clinical trial.

          7. Serum HBV DNA-negative by DNA PCR-amplification assay (lower detection limit 102
             genomes/ml) just before inclusion in the clinical trial.

          8. Continuous and interrupted prophylaxis with HBIG after an-hepatic phase as part of the
             subject clinical care.

          9. Trough serum HBsAg Ab (HBsAg IgG) titer (immediately pre-dose) &gt; 150 I.U./l in at
             least 2 consecutive determinations within last 3 months before inclusion in the
             clinical trail.

         10. Signed informed consent.

        Exclusion Criteria:

          1. Serum HBsAg-positive just before inclusion in the clinical trial.

          2. Serum HBeAg-positive within 3 months before transplantation.

          3. Serum HBV DNA-positive by standard DNA hybridisation assay (lower detection limit 105
             genomes/ml), or by any less sensitivity technique, within 3 months before
             transplantation.

          4. Unknown serum HBV replication status (no data about HbeAg and HBV DNA) within 3 months
             before transplantation.

          5. Previous recurrence of HBV in the transplanted liver defined by serum HBV DNA-
             positive by sensitive hybridisation (lower detection limit 105 genomes/ml) assay or
             any less sensitive technique, and/or serum HBeAg-positive, and/or serum
             HBsAg-positive.

          6. Re-transplanted liver even for reasons not related to HBV infection.

          7. Evidence of hepatocellular carcinoma in the transplanted liver, or metastatic disease,
             at time of inclusion in the clinical trial.

          8. Evidence of graft rejection at time of inclusion in the clinical trial.

          9. Life-expectancy less than 1 year.

         10. VHC infection.

         11. HIV type 1 or type 2 infection.

         12. Acute HAV infection.

         13. Previous treatment with i.m. HBIG Grifols within 3 months before inclusion in the
             clinical trial.

         14. Intolerance or allergy to any i.m. HBIG Grifols containing substance (glycine, sodium
             chloride, sterile water for injection, homologous human immune globulin).

         15. History of SAEs related to the administration of human blood-derived products.

         16. History of frequent AEs, even non-serious, related to the administration of human
             blood-derived products.

         17. Selective IgA deficiency with Abs against IgA.

         18. Platelet count &lt; 50 x 109/L.

         19. Prothrombin time (PT) &lt; 60%.

         20. Activated partial thromboplastin time (APTT) ratio &gt; 1.5.

         21. Any haemostatic abnormality contraindicating i.m. injection according to
             investigator's judgement.

         22. Haemoglobin &lt; 11 g/dl.

         23. Alcohol or drug abuse at the moment or within 1 year before inclusion in the clinical
             trial.

         24. Pregnant woman or woman who is expecting to be pregnant within 1 year after inclusion
             in the clinical trial.

         25. Breast-feeding woman.

         26. Any severe acute or chronic medical, surgical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration, or may interfere with the interpretation of
             study results and, in the judgment of the investigator, makes the subject
             inappropriate for entry in this clinical trial.

         27. Impossibility to donate a serum sample before the first investigational product
             administration.

         28. Planned treatment with Ig other than i.m. HBIG Grifols within the clinical trial
             period.

         29. Planned modification, during the clinical trial period, of the prophylactic regimen
             with nucleoside analogues followed by the subjects, if any, within last 3 months
             before inclusion in the clinical trial.

         30. The subject has been previously admitted to this clinical trial.

         31. Participation in other clinical trial within 3 months before study inclusion.

         32. Subject's incapacity of giving consent personally.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Filipponi, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Transplantation Co-ordinating Section. Cisanello Hospital. (University of Pisa).</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cisanello Hospital. (University of Pisa).</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedaliera Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Antonio PÃ¡ez, MD</name_title>
    <organization>Instituto Grifols S.A.</organization>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <keyword>Anti-hepatitis B antibodies</keyword>
  <keyword>Immunoglobulins</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>Protective levels</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Intramuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

